The float is reasonable for a non revenue clinical
Post# of 36536
(Total Views: 291)
Posted On: 09/24/2021 5:45:26 PM
The float is reasonable for a non revenue clinical research OTC biotech. As an example CYDY was at similar price levels with nearly 4 times the OS and went to $10. Currently at $2.33 with 645,000,000 in the OS count.
Having said that, I would be very happy for the rest of the financing to come through so we don't continue this dilution.
Having said that, I would be very happy for the rest of the financing to come through so we don't continue this dilution.
(1)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼